Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 59-66

  Chang, Nancy N ^a   Murray, Cynthia K ^b   Houck, Peter M ^c   Bratzler, Dale W ^b   Greenway, Claudette ^b   Guglielmo, B Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oklahoma Foundation for Medical Quality   (United States)

^c Centers for Medicare and Medicaid Services   (United States)

Author keywords

Allergy history; Community acquired pneumonia; Culture results; Fluoroquinolone; Fluoroquinolone resistant bacteria; Gram negative bacteria; Gram positive bacteria

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; UREIDOPENICILLIN DERIVATIVE;

ALLERGY; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; PENICILLIN ALLERGY; RETROSPECTIVE STUDY; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

BLOOD; COMMUNITY-ACQUIRED INFECTIONS; DATA COLLECTION; DRUG HYPERSENSITIVITY; FLUOROQUINOLONES; HUMANS; MALE; MEDICAL RECORDS; MICROBIOLOGICAL TECHNIQUES; PENICILLINS; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, PNEUMOCOCCAL; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 11144239779     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.59.55627     Document Type: Article

References (28)

1. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000;160:1399-408.
2. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society: the Canadian community-acquired pneumonia working group. Clin Infect Dis 2000;31:383-421.
4. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
5. Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998;129:908-10.
6. Intraagency Task Force on Antimicrobial Resistance, Cochairs: Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, Agency for Healthcare Research and Quality, Health Care Financing Administration, Health Resources and Services Administration, Department of Agriculture, Department of Defense, Department of Veterans Affairs, Environmental Protection Agency. A public health action plan to combat antimicrobial resistance, 2001. Available from http://www.cdc. gov/ drugresistance/actionplan/html/index.htm. Accessed December 1, 2003.
7. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002;35:1505-11.
8. Campo L, Mylotte JM. Use of microbiology reports by physicians in prescribing antimicrobial agents. Am J Med Sci 1998;296:392-8.
9. Chalasani NP, Valdecanas MA, Gopal AK, McGowan JE Jr, Jurado RL. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995;108:932-6.
10. Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278-81.
11. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
12. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-92.
13. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones: Unites States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001;50:800-4.
14. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian bacterial surveillance network. N Engl J Med 1999;341:233-9.
15. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
16. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002;8:594-7.
17. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST surveillance program (1998-2002). Clin Infect Dis 2003;36:963-70.
18. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
19. Anderson KB, Tan JS, File TM, DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-81.
20. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
21. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-9.
22. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(suppl 1):25-37.
23. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
24. Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America). Diagn Microbiol Infect Dis 2001;40:129-36.
25. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents 2001;17:357-63.
26. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonos aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8.
27. Johnson CK, Tomes H, Polk RE. Community fluoroquinolone (FQ) use and its relationship to hospital rates of ciprofloxacin-resistant Pseudomonas aeruginosa (CRPa): a SCOPE-MMIT report [abstr). In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:321.
28. Tan MJ, Tan JS, File TM Jr. Legionnaire's disease with bacteremic coinfection. Clin Infect Dis 2002;35:533-9.